ArticleMicroorganisms2026
Development of a Controlled-Dose Aerosol Challenge Method Using a Lung Fluid Quantitative Nebulizer.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Airborne transmission represents a primary route of influenza virus dissemination. In animal infection models, conventional intranasal instillation fails to recapitulate the physiological features of natural respiratory infection. Existing aerosol-based challenge methods-including whole-body inhalation and oronasal exposure-face limitations in precise quantification of the delivered infectious dose. Moreover, oronasal exposure systems require specialized, high-cost instrumentation. This study established an economical and dosing-controlled aerosol challenge method utilizing a lung fluid quantitative nebulizer, which can deliver aerosolized virus directly to the lower respiratory tract via endotracheal intubation. The count median aerodynamic diameter (CMAD) of aerosols generated by the nebulizer was 2.28 μm. We compared pulmonary deposition efficiency and pathogenicity between lung-delivery aerosol inhalation and conventional intranasal instillation of PR8 influenza virus in mice. The pulmonary deposition rate for the aerosol inhalation was 63.1%, with an LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.